Drug Chatter -- Tracking biopharma stock chatter

Profile for GlobeImmune, Inc. (GBIM)

« Back to company index

GBIM Chatter Timeline

Stock Ticker for GBIM

Most Active Tweeters for GBIM

UserTweets
@CatalystWatcher 2
@PhillyPhils2012 1
@KingPhil23 1
@American_Bulls 1

Recent Tweets for GBIM

CatalystWatcher @CatalystWatcher
I count 9 $GBIM & $NK combo vaccine trials set to start in December. These are the backbone trials of… https://t.co/0NAhv409nC
December 6th 2017, 12:12pm
PhillyPhils2012 @PhillyPhils2012
$GBIM ......? https://t.co/pqzK0nFkPP
December 5th 2017, 6:12pm
KingPhil23 @KingPhil23
RT @American_Bulls: $GBIM may go up 46% if the bull pattern is confirmed. Chk confirmation [60%] @ https://t.co/7jGtSVVGTX. Buy level:0.549…
December 5th 2017, 6:12pm
American_Bulls @American_Bulls
$GBIM may go up 46% if the bull pattern is confirmed. Chk confirmation [60%] @ https://t.co/7jGtSVVGTX. Buy level:0.5495.
December 5th 2017, 6:12pm
CatalystWatcher @CatalystWatcher
$GBIM Another two employees hired on linkedin over past week, including a Research Scientist for internal TB progra… https://t.co/7JCqIeLiC9
December 4th 2017, 1:12pm
RatingsNetwork @RatingsNetwork
Globeimmune upgraded by ValuEngine to hold. https://t.co/k7mSFEuUFT $GBIM #GBIM
November 20th 2017, 10:11pm
ConsumerFeed @ConsumerFeed
Globeimmune upgraded by ValuEngine to hold. https://t.co/Oe1tFMZ1q6 $GBIM #GBIM
November 20th 2017, 10:11pm
CatalystWatcher @CatalystWatcher
$GBIM volume. merger news do out any day.
November 20th 2017, 3:11pm
CatalystWatcher @CatalystWatcher
Correct link: https://t.co/29z4fQP6sR $GBIM
November 17th 2017, 5:11pm
CatalystWatcher @CatalystWatcher
$GBIM watching for those 11 QUILT trials to start any day now. Long overdue to hear something from @nantcell
November 17th 2017, 10:11am
CatalystWatcher @CatalystWatcher
Remaining QUILT $GBIM $NK trials to begin recruitment shortly as FDA approved IND for hANK in October per 10q. Big… https://t.co/CjHak8m45E
November 8th 2017, 12:11pm
StockflareUS @StockflareUS
$GBIM: The MACD technical indicator for GlobeImmune Inc has just fallen below zero indicating a negative signal. (https://t.co/m4EEqQxcd8)
November 3rd 2017, 5:11am
CatalystWatcher @CatalystWatcher
$GBIM European patent application activity for yeast-brachyury immunotherapy - https://t.co/RbMBp2Wgsq
November 2nd 2017, 7:11pm
CatalystWatcher @CatalystWatcher
$GBIM GI-6207 SITC data will be out next Friday, November 10. https://t.co/8E3Gwrq3Ac https://t.co/hahH5WQ4ae
November 2nd 2017, 2:11pm
CatalystWatcher @CatalystWatcher
New Phase 1b/2 trial using $GBIM GI-4000 in Pancreatic Cancer. https://t.co/20YCwfElfI
November 1st 2017, 12:11pm
RunnersDad @RunnersDad
@CatalystWatcher I did not look at all of the trials but that would make sense. How are you anticipating they will handle $GBIM?
October 31st 2017, 1:10pm
CatalystWatcher @CatalystWatcher
$GBIM all studies now starting 12/2017. Big announcement coming in November for NantCell merger & NantBio IPO. https://t.co/UpD7WY57s6
October 31st 2017, 1:10pm
CatalystWatcher @CatalystWatcher
Some major changes on https://t.co/cFKqOqfHGO for $GBIM QUILT Trials. NantCell no longer sponsor and study contact has a @nantbio.com email.
October 31st 2017, 1:10pm
specstockspulse @specstockspulse
Research $GBIM with social data, financial data and a wealth of other data. No login required! https://t.co/xEk4kz0pke
October 30th 2017, 7:10pm
CatalystWatcher @CatalystWatcher
$GBIM full GI-6207 data at SITC next week. Additionally, looking for QUILT trial initiations, NantCell merger and NantBio IPO filing in Nov
October 30th 2017, 11:10am
specstockscom @specstockscom
Customized research for $GBIM vs. $PPHM! #stocks https://t.co/KDXcNtgOll
October 30th 2017, 10:10am
specstockspulse @specstockspulse
Get your say in on $GBIM at SpeculatingStocks, the discovery engine. No login required! #stocks https://t.co/j9RjcFcSmh
October 28th 2017, 12:10am
specstockscom @specstockscom
Get your say in on $GBIM at SpeculatingStocks, the discovery engine. No login required! #stocks https://t.co/6MITansHSE
October 28th 2017, 12:10am
toronto_orlando @toronto_orlando
$GBIM @zoomlik1 I'm not subscribed to I V but I've been reading it. I can open accounts for my 4 kids and buy a few shares. Let's do this
October 27th 2017, 1:10pm
CatalystWatcher @CatalystWatcher
One perk to a billionaire fully funding your investment + holding a majority stake - Stock is immune to market fluctuations. $GBIM
October 25th 2017, 1:10pm
CatalystWatcher @CatalystWatcher
@Zoomlik1 @DrPatSoonShiong Both are equally possible. My point is $GBIM is involved given their 200k NantCell share… https://t.co/UUru0zYULe
October 24th 2017, 3:10pm
Zoomlik1 @Zoomlik1
RT @CatalystWatcher: $CELG Q3 ER this Thursday. 10q may disclose what happened to $GBIM license agreement for GI-6207 + GI-6301 and how Nan…
October 23rd 2017, 11:10pm
CatalystWatcher @CatalystWatcher
$CELG Q3 ER this Thursday. 10q may disclose what happened to $GBIM license agreement for GI-6207 + GI-6301 and how NantCell "acquired" it.
October 23rd 2017, 1:10pm
CatalystWatcher @CatalystWatcher
@BreakoutBull $GBIM was given 200k NC shares in March, which suggests they are to be a part of upcoming NantCell me… https://t.co/HGYF45XyU1
October 23rd 2017, 9:10am
BreakoutBull @BreakoutBull
@CatalystWatcher You’ve been highly accurate on past picks and I like this $GBIM setup. Do we have a PT or is it pending IPO deal?
October 23rd 2017, 6:10am
CatalystWatcher @CatalystWatcher
Nice to see some media interest in $GBIM's GI-6207. Looking forward to SITC where full data should be disclosed. https://t.co/ewP7Vd2UyH
October 20th 2017, 1:10pm
CatalystWatcher @CatalystWatcher
RT @CaesarBiotech: $GBIM #Thyroid2017 https://t.co/DDj9yqmvNc
October 19th 2017, 2:10pm
CaesarBiotech @CaesarBiotech
$GBIM #Thyroid2017 https://t.co/DDj9yqmvNc
October 19th 2017, 2:10pm
CatalystWatcher @CatalystWatcher
@moralesjohnp $GBIM breaking out from LT pennant pattern. $1 test coming.
October 19th 2017, 12:10pm
CatalystWatcher @CatalystWatcher
RT @moralesjohnp: $GBIM at breakout point, see image below https://t.co/gR7997j7E8
October 18th 2017, 2:10pm
moralesjohnp @moralesjohnp
$GBIM at breakout point, see image below https://t.co/gR7997j7E8
October 18th 2017, 2:10pm
CatalystWatcher @CatalystWatcher
Over 60 days into @nantcell quiet period. Expect Merger/IPO announcement, including $GBIM, within 30 days or less based on industry norm.
October 17th 2017, 11:10am
CatalystWatcher @CatalystWatcher
I count 12 FULLY FUNDED Phase 2 $GBIM assets in development + 2 pre-clinical internal R&D programs. Market is wising up ahead of Nant IPO.
October 16th 2017, 12:10pm
CatalystWatcher @CatalystWatcher
$GBIM GI-6207 case study abstract being presented next week at ATA. Full Phase 2 data at SITC in November. https://t.co/jIEdloNy9p
October 15th 2017, 12:10pm
CatalystWatcher @CatalystWatcher
RT @CaesarBiotech: $GBIM brachyury vaccine - ph1 evidence of clinical activity - ph2 ongoing. https://t.co/ZUvl9oPc5j
October 13th 2017, 5:10pm
CaesarBiotech @CaesarBiotech
$GBIM brachyury vaccine - ph1 evidence of clinical activity - ph2 ongoing. https://t.co/ZUvl9oPc5j
October 13th 2017, 3:10pm
jwbartelt @jwbartelt
RT @CaesarBiotech: $GBIM Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer. - PubMed - NCBI https://t.co/AOIXj4NADi
October 12th 2017, 3:10pm
CatalystWatcher @CatalystWatcher
$GBIM patent activity for HIV. https://t.co/jEQ57bGEyl
October 12th 2017, 1:10pm
CaesarBiotech @CaesarBiotech
$GBIM Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer. - PubMed - NCBI https://t.co/AOIXj4NADi
October 12th 2017, 6:10am
CatalystWatcher @CatalystWatcher
First look at $GBIM GI-6207 immunological response data in MTC at #thyroid #ATA next week.
October 11th 2017, 12:10pm
CatalystWatcher @CatalystWatcher
$GBIM now up to 23 employees on Linkedin. https://t.co/vV2auSK5eB. Market cap sitting at $9 million with GI-6207 data coming + NantCell IPO
October 9th 2017, 1:10pm
CatalystWatcher @CatalystWatcher
@Zoomlik1 @DrPatSoonShiong If $GBIM was still on NASDAQ and disclosed its true cash position and value of the licen… https://t.co/Asx8urLEet
October 5th 2017, 2:10pm
CatalystWatcher @CatalystWatcher
RT @Zoomlik1: @DrPatSoonShiong gets it $gbim must be + Avelumab Nk cells must + CD16 + Avelu. IL15 catalyst Rad. +chemo flags Now BUY…
October 5th 2017, 12:10pm
CatalystWatcher @CatalystWatcher
@Zoomlik1 @DrPatSoonShiong If NantCell disclosed milestone payments + $GBIM cash position, stock would be multiples… https://t.co/V2YsZ7XqUz
October 4th 2017, 1:10pm
CatalystWatcher @CatalystWatcher
$GBIM early evidence that GI-6207 enhances PD-L1 expression, which could lead to sig. drops in Calcitonin in MTC. https://t.co/Cde9Q0fHIN
October 4th 2017, 9:10am

Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.